October 29, 2024 10:49 AM EDTUpdated 12:50 PM
R&D

Two type 1 di­a­betes pa­tients are in­sulin-free af­ter Ele­don's im­muno­sup­pres­sant and an islet trans­plant

Katherine Lewin

News Reporter

Ele­don Phar­ma­ceu­ti­cals’ ex­per­i­men­tal im­muno­sup­pres­sant helped two pa­tients with type 1 di­a­betes go in­sulin-free fol­low­ing an islet cell trans­plant, the com­pa­ny an­nounced Tues­day.

The com­pa­ny’s stock …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times